146 related articles for article (PubMed ID: 38289085)
1. Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor.
Wang X; Tang H; Bie Z; Wang Y; Yuan R; Zhang Z; Xiong Z; Yang Z; Bi Z; Wang B; Liu P
Neurosurgery; 2024 Jan; ():. PubMed ID: 38289085
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
3. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.
Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148
[TBL] [Abstract][Full Text] [Related]
5. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1.
Fookeerah P; Varikatt W; Shingde M; Dexter MAJ; McLean M
Endocr Connect; 2023 Nov; 12(11):. PubMed ID: 37851558
[TBL] [Abstract][Full Text] [Related]
7. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
8. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
9. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
10. Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?
Lee CH
Brain Tumor Res Treat; 2023 Jul; 11(3):173-176. PubMed ID: 37550816
[TBL] [Abstract][Full Text] [Related]
11. Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives.
Wan XY; Chen J; Wang JW; Liu YC; Shu K; Lei T
Curr Med Sci; 2022 Dec; 42(6):1111-1118. PubMed ID: 36544040
[TBL] [Abstract][Full Text] [Related]
12. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Raverot G; Roncaroli F; Villa C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098443
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenomas with multiple cell lineage combinations: clinicopathological features and short-term prognosis.
Tang H; Wang X; Bie Z; Yang Z; Wang B; Li S; Liu P
J Neurosurg; 2023 Sep; 139(3):810-821. PubMed ID: 36708537
[TBL] [Abstract][Full Text] [Related]
14. [WHO Histological Classification of Pituitary Tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract][Full Text] [Related]
15. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
Kurosaki M
No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
[TBL] [Abstract][Full Text] [Related]
16. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
[No Abstract] [Full Text] [Related]
17. Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET.
Zhang Q; Yao B; Long X; Chen Z; He M; Wu Y; Qiao N; Ma Z; Ye Z; Zhang Y; Yao S; Wang Y; Cheng H; Chen H; Ye H; Wang Y; Li Y; Chen J; Zhang Z; Guo F; Zhao Y
Cell Rep Med; 2023 Feb; 4(2):100934. PubMed ID: 36754052
[TBL] [Abstract][Full Text] [Related]
18. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
[TBL] [Abstract][Full Text] [Related]
19. [Histological Classification and Diagnosis of Sellar/Parasellar Tumors].
Nishioka H
No Shinkei Geka; 2023 Sep; 51(5):789-798. PubMed ID: 37743330
[TBL] [Abstract][Full Text] [Related]
20. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
